MHRAapproval83% confidence
Clinical trials for medicines: modifying a clinical trial approval
Source: MHRA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (lung cancer) as Janssen.
Regulatory Analysis
Guidance on the various types of modifications that can be made to a clinical trial approval.
Supporting Context
- Therapeutic area
- Oncology · NSCLC
- Sub-indication
- Lung Cancer
Related signal: Janssen's Amivantamab and Docetaxel Combo in NSCLC Enters Phase 1/2 Trials